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GUEST EDITORIAL
Hepatocellular carcinoma
Much of the progress in the developing field of
hepatocellular carcinoma (HCC) depends on general
progress: in public health initiatives based on improved
knowledge in epidemiology, in many non-cancer-
related areas such as antiviral therapeutics and
treatment of chronic liver diseases leading to cancer
prevention, in diagnostic modalities making early
tumour detection possible, in accurate staging which
guides better treatment selection, and in non-surgical
and surgical treatments leading to improved safety and
improved prognosis.
In the current issue, Leong & Leong outline the
marked geographical variation of HCCworldwide, and
emphasize the magnitude of the problem, which is
becoming increasingly important in the western world,
with increasing rates of hepatitis C (HCV) infection.
Research into the aetiological factors of HCC leads to
the conclusion that as with other carcinomas, HCC
develops by a multi-step mechanism which involves
complex interactions between multiple factors. Envi-
ronmental factors which have been found to be closely
related to HCC are chronic hepatitis B (HBV) infec-
tion, HCV infection, chemical carcinogens and plant
toxins. Although chronic alcohol abuse often compli-
cates HCC, alcohol is not a cirrhosis-causing agent and
has not been shown to have a carcinogenic effect
in the liver. However, alcohol may play a role as a co-
carcinogen with other agents. Smoking also induces
the cytochrome P450 system, thus having a synergistic
effect with alcohol and chronic HBV infection, and is a
significant risk factor for HCC in some countries.
Some genetic diseases and inborn errors of metab-
olism are known to be associated with HCC. HCC
displays numerous genetic abnormalities, mutations
and epigenetic alterations. Because HCC exhibits a
high degree of genetic heterogeneity, it is likely that
multiple molecular pathways are involved in the
production of subsets of hepatocellular tumours. The
concept of premalignant lesions of the liver and cellular
alterations preceding fully developed HCC has been
controversial. It is interesting to note from this article
the diagnostic criteria used by histopathologists for
early HCC. It is also very educational for a clinician to
understand the meanings of the terms used by the
histopathologists such as dysplastic nodule (and its
synonyms), nodular regenerative hyperplasia, and
large and small liver cell dysplasia.
The high incidence of HCC and its poor prognosis
are the two reasons that are especially relevant in
considering the need to prevent this tumour. Primary
prevention lends itself particularly well to viral,
chemical and physical causes of HCC. Primary
prevention could best be accomplished by immuniza-
tion against HBV. Unfortunately, despite considerable
research over a number of years, there appears to be
little likelihood of a vaccine against HCV becoming
available in the near future. Other forms of primary
prevention against HBV and HCV include safe
injection practices, screening of donated blood for
the presence of hepatitis viruses, the rational use of
viral inactivation steps in the manufacture of blood
products, passive immunization and antiviral agents.
Aflatoxin B1 is the most potent human hepatocar-
cinogen and it is produced by the fungi Aspergillus
flavus and A. parasiticus. Attempts at primary pre-
vention in this area need to focus on minimizing
contamination by these fungi during the growth of
crops and improper storage.
Dietary iron overload in Black Africans in urban
parts of sub-Saharan Africa has virtually disappeared as
a result of a change in their drinking habits from home-
brewed sorghum-based beverages with a high iron
content to commercially available iron-free varieties of
alcohol. However, the pattern of alcohol consumption
in rural areas remains largely unchanged and a large-
scale intervention programme has yet to be attempted.
Attempts have also been made in China to urge the
rural population to drink running water or deep well-
water to prevent the population from using ditch, pond
or river water contaminated by blue-green algae that
produce microcystins. Minor risk factors are oral con-
traceptive steroids and smoking. Secondary prevention
entails the use of natural or synthetic chemicals to
block, retard, or reverse the carcinogenic process.
Preliminary evidence indicates that chemoprevention
might be possible with the use of chlorophyllin, oltipraz
and polyprenoeic acid. A decrease in the risk of HCC
correlates with an increased consumption of leafy,
green vegetables. Other chemoprevention possibilities
include the use of glycosinolates and isothiocyanates
from broccoli sprouts. The ‘de-ironing’ of patients with
hereditary haemochromatosis by repeated venesection
would be expected to have a secondary preventive
effect against HCC formation both by reversing the
accumulation of iron and by preventing the develop-
ment of cirrhosis. Attempts have also been made in
tertiary prevention of HCC to prevent the progression
of chronic hepatitis or cirrhosis to HCC by treating the
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preneoplastic virally induced necroinflammation.
Interferon-alpha has been used for both HCV- and
HBV-induced diseases, and glycyrrhizin has been tried
in chronic HCV infection. These agents may be
regarded as being immunopreventive by functioning as
biological response modifiers. An excellent article by
Kew on the prevention of HCC appears in this issue
of HPB.
In recent years the focus of much research on HCC
has revolved around diagnostic strategies to identify
early HCC, which is potentially amenable to curative
therapy. HCC classically arises and grows in a silent
fashion, making its diagnosis challenging prior to the
development of late stage disease. Although surveil-
lance of individuals at risk for HCC is an attractive
strategy for early diagnosis, whether screening is cost-
effective is still a matter of controversy. The cost of
surveillance for HCC varies according to the region,
population incidence and screening tools used. The
clinical presentations of patients with HCC relate to
the extent of the tumour, the hepatic reserve at the time
of diagnosis and whether the tumours present with
complications (such as tumour rupture), metastases or
paraneoplastic phenomena. Bialecki & Di Bisceglie
have provided an excellent review on the role of tumour
markers, ultrasound, computed tomography, magnetic
resonance imaging, angiography and positron emission
tomography in diagnosing and staging HCC. Further-
more, the value and the potential risks of liver biopsy
are discussed in this article on the diagnosis of HCC.
Cancer staging should serve to select the appropriate
primary and adjuvant therapy, to estimate the
prognosis, to assist in the evaluation of the results of
treatments, and to exchange information without
ambiguity. In HCC, apart from treatment efficacy,
patient survival is related to tumour stage, degree of
liver function impairment of the underlying cirrhotic
liver and the general health status of the patient. The
article by Pons et al. on the staging systems for HCC
discusses in detail the staging systems that are currently
in use in different parts of the world. Some of
these staging systems use tumour stage and its variables
only (ER classification) while some use tumour
stage (and its variables) and liver function (Okuda
stage, CLIP classifications, TNM staging), whereas
others use tumour stage (and its variables), liver
function and health status of the patients (French
classification, BCLC staging and CUPI index). The
value and the limitations of each of these staging
systems are reviewed, making this article very inter-
esting to read.
Surgery, including liver transplantation (LT),
remains the most efficient treatment for patients with
HCC. Unfortunately only about 15–30% of patients
are eligible for surgical treatment at the time of clinical
presentation because of the extent of the tumour and
associated cirrhosis. HCC which develops in a non-
cirrhotic liver has a much better long-term result than
in cirrhosis. These favourable results are observed in
both fibrolamellar and non-fibrolamellar HCC vari-
ants, suggesting that the absence of underlying liver
disease is a major factor in short- and long-term
prognosis. In the article by Belghiti & Kianmanesh on
surgical treatment of HCC, details are given on the
indications for hepatectomy, preoperative evaluation
of liver functional reserve, extent of resection, and
factors that lead to improvements in results of surgical
resection, including the use of intermittent inflow
occlusion and anterior approach. The approach to
recurrence following resection of HCC and the results
of liver resection are also reviewed. This article also
covers LT for the treatment ofHCC, including tumour
management while awaiting LT and the increasing
use of living donor LT. Living donor LT opens the
potential for the expansion of the Milan criteria, which
are now commonly used.
Recent developments suggest that apart from
surgery, other therapeutic modalities such as radio-
frequency ablation (RFA) and percutaneous ethanol
injection (PEI) are also potentially ‘curative’. Johnson
in his excellent article reviews the non-surgical treat-
ment of HCC. He classifies the non-surgical treatment
into locoregional (which includes intra-arterial or
percutaneous local ablative approaches) or systemic
therapy. These different types of treatment can be
combined in the treatment of HCC. Intra-arterial
therapy reviewed by the author includes transcatheter
oily chemoembolization or internal radiation with
intra-arterial radioisotopes. Local ablative therapies
reviewed include PEI, RFA, cryotherapy and laser
ablation. Systemic therapies reviewed include systemic
chemotherapy, and hormonal and biotherapy. Loco-
regional therapies are capable of delivering complete
local control of HCC in a percentage of patients, the
percentage decreasing as the tumour size increases.
Unfortunately recurrence after local control might be a
rule. To date, systemic therapy has not convincingly
been demonstrated to be effective in the treatment
of HCC.
This special issue on hepatocellular carcinoma
contains articles from experts from different parts of
the world. The topics and the authors have been
carefully chosen and the articles have been extremely
well written. I am sure that these articles will be
referred to by future authors for many years to come.
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